Lucid Diagnostics Secures Medicare Reimbursement for EsoGuard Test and $15 Million Financing

On October 22, 2026, Lucid Diagnostics Inc. announced a significant breakthrough in cancer prevention as it began receiving reimbursement from Medicare for its EsoGuard® Esophageal DNA Test. This pivotal development marks the first time Medicare beneficiaries across the nation have access to this groundbreaking test, which aims to detect esophageal cancer, a serious health condition that affects many individuals with gastroesophageal reflux disease (GERD).

Dr. Lishan Aklog, Chairman and CEO of Lucid, expressed enthusiasm about this new phase in the company's operations. He stated, "For the first time, Medicare beneficiaries nationwide have fully reimbursed access to the groundbreaking EsoGuard test. This breakthrough marks a seminal moment in our mission to end the scourge of esophageal cancer through precancer testing of at-risk patients." This new reimbursement policy not only represents a crucial advancement for patients but also opens up immediate commercial opportunities for the company, expanding its reach beyond primary care and into specialized gastroenterology and geriatric practices.

Adding to the positive news, Lucid Diagnostics also closed a $15 million private placement of its Series C Convertible Preferred Stock on October 21, enhancing its financial standing and extending its cash runway. The investment came primarily from existing long-term shareholders, strengthening the company's balance sheet at a critical moment. Dr. Aklog noted that this infusion of capital would aid in accelerating commercial efforts to promote EsoGuard further.

The reimbursement process commenced shortly after the company announced on September 22 that it would begin submitting claims for EsoGuard tests performed at their CLIA-certified laboratories. Under the established Clinical Laboratory Fee Schedule, each test reimbursed by Medicare is valued at $1,938.01, providing a considerable source of revenue potential for Lucid.

The Series C Preferred Stock sold at a price of $1,000 per share and can be converted into common stock at a conversion price of $0.3519 per share, giving investors and stakeholders a pathway to engage further with the company's evolving financial landscape. This round of financing also addressed existing concerns related to Medicare's payment mechanisms, particularly regarding default provisions tied to the company's 12.0% senior secured convertible notes due in 2029.

Through these advancements, Lucid Diagnostics is not just enhancing its operational capabilities; it’s also creating a broader safety net for individuals at risk of esophageal cancer. The EsoGuard test, which is non-invasive, is designed to detect precancerous conditions early, thereby potentially saving lives while also addressing the increasing healthcare demands related to esophageal conditions.

Looking ahead, Lucid Diagnostics is committed to translating this momentous achievement into tangible commercial outcomes. The company aims to solidify its position in the healthcare market by pursuing further coverage options with commercial payors while remaining focused on ensuring that the EsoGuard test is widely adopted across the healthcare system.

As Lucid progresses, stakeholders and patients alike look forward to continual improvements in the early detection of esophageal cancer and the remaining challenges in public health regarding gastrointestinal diseases. The expansion of Medicare reimbursement not only provides critical financial support for Lucid Diagnostics but also enhances patient access to essential diagnostic tools designed to combat one of the most preventable types of cancer.